
Manuel Elkin Me Patarroyo Murillo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2931159/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cervical cancer screening programme attendance and compliance predictors regarding Colombia's Amazon region. PLoS ONE, 2022, 17, e0262069.	2.5	0
2	The Cellular and Molecular Interaction Between Erythrocytes and Plasmodium falciparum Merozoites. Frontiers in Cellular and Infection Microbiology, 2022, 12, 816574.	3.9	6
3	SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World's Population. Frontiers in Immunology, 2022, 13, .	4.8	0
4	A novel platform for peptide-mediated affinity capture and LC-MS/MS identification of host receptors involved in Plasmodium invasion. Journal of Proteomics, 2021, 231, 104002.	2.4	7
5	The molecular basis for peptide-based antimalarial vaccine development targeting erythrocyte invasion by P.Âfalciparum. Biochemical and Biophysical Research Communications, 2021, 534, 86-93.	2.1	3
6	MHCBI: a pipeline for calculating peptide-MHC binding energy using semi-empirical quantum mechanical methods with explicit/implicit solvent models. Briefings in Bioinformatics, 2021, 22, .	6.5	2
7	Identifying HLA DRB1-DQB1 alleles associated with Chlamydia trachomatis infection and in silico prediction of potentially-related peptides. Scientific Reports, 2021, 11, 12837.	3.3	4
8	The First Chemically-Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped Aotus Monkeys for Human Use. Frontiers in Immunology, 2021, 12, 724060.	4.8	5
9	Molecular characterisation of parvorder Platyrrhini IgG sub-classes. Molecular Immunology, 2021, 139, 23-31.	2.2	2
10	Mycobacterium tuberculosis Rv0292 Protein Peptides Could be Included in a Synthetic Anti-tuberculosis Vaccine. International Journal of Peptide Research and Therapeutics, 2021, 27, 2823.	1.9	1
11	Trichomonas vaginalis follow-up and persistence in Colombian women. Scientific Reports, 2021, 11, 22597.	3.3	2
12	How to Combat Gram-Negative Bacteria Using Antimicrobial Peptides: A Challenge or an Unattainable Goal?. Antibiotics, 2021, 10, 1499.	3.7	19
13	Shorter Antibacterial Peptide Having High Selectivity for E. coli Membranes and Low Potential for Inducing Resistance. Microorganisms, 2020, 8, 867.	3.6	7
14	Antibodies targeting Mycobacterium tuberculosis peptides inhibit mycobacterial entry to infection target cells. International Journal of Biological Macromolecules, 2020, 161, 712-720.	7.5	3
15	Identifying the HLA DRB1-DQB1 molecules and predicting epitopes associated with high-risk HPV infection clearance and redetection. Scientific Reports, 2020, 10, 7306.	3.3	9
16	Hotspots in Plasmodium and RBC Receptor-Ligand Interactions: Key Pieces for Inhibiting Malarial Parasite Invasion. International Journal of Molecular Sciences, 2020, 21, 4729.	4.1	11
17	Plasmodium falciparum pre-erythrocytic stage vaccine development. Malaria Journal, 2020, 19, 56.	2.3	36
18	p―Methoxyphenol: A potent and effective scavenger for solidâ€phase peptide synthesis. Journal of Peptide Science, 2020, 26, e3251.	1.4	1

#	Article	IF	CITATIONS
19	Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates. Vaccine, 2020, 38, 3942-3951.	3.8	6
20	Malaria: Paving the way to developing peptide-based vaccines against invasion in infectious diseases. Biochemical and Biophysical Research Communications, 2020, 527, 1021-1026.	2.1	5
21	Designing and optimizing new antimicrobial peptides: all targets are not the same. Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 351-373.	6.1	35
22	Using nextâ€generation sequencing for characterising HLA―DRB1 and DQB1 loci in a cohort of Colombian women. Hla, 2019, 94, 425-434.	0.6	1
23	Specific Binding Peptides from Rv3632: A Strategy for BlockingMycobacterium tuberculosisEntry to Target Cells?. BioMed Research International, 2019, 2019, 1-13.	1.9	3
24	Behavior and abundance of Anopheles darlingi in communities living in the Colombian Amazon riverside. PLoS ONE, 2019, 14, e0213335.	2.5	9
25	Assessing Peptide Binding to MHC II: An Accurate Semiempirical Quantum Mechanics Based Proposal. Journal of Chemical Information and Modeling, 2019, 59, 5148-5160.	5.4	5
26	Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines. Frontiers in Microbiology, 2019, 10, 2712.	3.5	17
27	Preliminary Evaluation of the Safety and Immunogenicity of an Antimalarial Vaccine Candidate Modified Peptide (IMPIPS) Mixture in a Murine Model. Journal of Immunology Research, 2019, 2019, 1-12.	2.2	2
28	Micro-epidemiology of mixed-species malaria infections in a rural population living in the Colombian Amazon region. Scientific Reports, 2018, 8, 5543.	3.3	19
29	Towards designing a synthetic antituberculosis vaccine: The Rv3587c peptide inhibits mycobacterial entry to host cells. Bioorganic and Medicinal Chemistry, 2018, 26, 2401-2409.	3.0	13
30	Simultaneous detection of Plasmodium vivax dhfr, dhps, mdr1 and crt-o resistance-associated mutations in the Colombian Amazonian region. Malaria Journal, 2018, 17, 130.	2.3	12
31	Synthetic Evaluation of Standard and Microwave-Assisted Solid Phase Peptide Synthesis of a Long Chimeric Peptide Derived from Four Plasmodium falciparum Proteins. Molecules, 2018, 23, 2877.	3.8	9
32	The in Vitro Antigenicity of Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2) B- and T-Epitopes Selected by HLA-DRB1 Binding Profile. Frontiers in Cellular and Infection Microbiology, 2018, 8, 156.	3.9	9
33	Mycobacterium tuberculosis H37Rv LpqG Protein Peptides Can Inhibit Mycobacterial Entry through Specific Interactions. Molecules, 2018, 23, 526.	3.8	5
34	Specific β-Turns Precede PPIIL Structures Binding to Allele-Specific HLA-DRβ1* PBRs in Fully-Protective Malaria Vaccine Components. Frontiers in Chemistry, 2018, 6, 106.	3.6	3
35	Association of HIV status with infection by multiple HPV types. Tropical Medicine and International Health, 2018, 23, 1259-1268.	2.3	15
36	The role of pi-interactions and hydrogen bonds in fully protective synthetic malaria vaccine development. Biochemical and Biophysical Research Communications, 2017, 484, 501-507.	2.1	12

#	Article	IF	CITATIONS
37	Functionally relevant proteins inPlasmodium falciparumhost cell invasion. Immunotherapy, 2017, 9, 131-155.	2.0	14
38	Identifying and characterising PPE7 (Rv0354c) high activity binding peptides and their role in inhibiting cell invasion. Molecular and Cellular Biochemistry, 2017, 430, 149-160.	3.1	6
39	Multiple high-risk HPV genotypes are grouped by type and are associated with viral load and risk factors. Epidemiology and Infection, 2017, 145, 1479-1490.	2.1	11
40	Critical role of HLA-DRÎ ^{2*} binding peptides' peripheral flanking residues in fully-protective malaria vaccine development. Biochemical and Biophysical Research Communications, 2017, 489, 339-345.	2.1	6
41	Semi-empirical quantum evaluation of peptide – MHC class II binding. Chemical Physics Letters, 2017, 668, 29-34.	2.6	12
42	Mass & secondary structure propensity of amino acids explain their mutability and evolutionary replacements. Scientific Reports, 2017, 7, 7717.	3.3	7
43	Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans. Biochemical and Biophysical Research Communications, 2017, 491, 1062-1069.	2.1	20
44	A Large Size Chimeric Highly Immunogenic Peptide Presents Multistage Plasmodium Antigens as a Vaccine Candidate System against Malaria. Molecules, 2017, 22, 1837.	3.8	4
45	Conserved Binding Regions Provide the Clue for Peptide-Based Vaccine Development: A Chemical Perspective. Molecules, 2017, 22, 2199.	3.8	9
46	Far from the Madding Crowd: the Molecular Basis for Immunological Escape ofPlasmodium falciparum. Current Issues in Molecular Biology, 2017, 22, 65-78.	2.4	7
47	A New Synthetic Peptide Having Two Target of Antibacterial Action in E. coli ML35. Frontiers in Microbiology, 2016, 7, 2006.	3.5	18
48	The Prevalence of High-Risk HPV Types and Factors Determining Infection in Female Colombian Adolescents. PLoS ONE, 2016, 11, e0166502.	2.5	14
49	Plasmodium malariae in the Colombian Amazon region: you don't diagnose what you don't suspect. Malaria Journal, 2016, 15, 576.	2.3	20
50	How frequently do clusters occur in hierarchical clustering analysis? A graph theoretical approach to studying ties in proximity. Journal of Cheminformatics, 2016, 8, 4.	6.1	11
51	Cellâ€Peptide Specific Interaction Can Inhibit <i>Mycobacterium tuberculosis H37Rv</i> Infection. Journal of Cellular Biochemistry, 2016, 117, 946-958.	2.6	6
52	TCR-contacting residues orientation and HLA-DRβ* binding preference determine long-lasting protective immunity against malaria. Biochemical and Biophysical Research Communications, 2016, 477, 654-660.	2.1	7
53	Mycobacterium tuberculosis PE9 protein has high activity binding peptides which inhibit target cell invasion. International Journal of Biological Macromolecules, 2016, 86, 646-655.	7.5	5
54	Chlamydia trachomatis Frequency in a Cohort of HPV-Infected Colombian Women. PLoS ONE, 2016, 11, e0147504.	2.5	12

#	Article	IF	CITATIONS
55	High Plasmodium malariae Prevalence in an Endemic Area of the Colombian Amazon Region. PLoS ONE, 2016, 11, e0159968.	2.5	31
56	The Malaria Parasite's Achilles' Heel: Functionally-relevant Invasion Structures. Current Issues in Molecular Biology, 2016, 18, 11-9.	2.4	5
57	Malaria Parasite Survival Depends on Conserved Binding Peptides' Critical Biological Functions. Current Issues in Molecular Biology, 2016, 18, 57-78.	2.4	11
58	Immune protection-inducing protein structures (IMPIPS) against malaria: the weapons needed for beating Odysseus. Vaccine, 2015, 33, 7525-7537.	3.8	14
59	IMPIPS: The Immune Protection-Inducing Protein Structure Concept in the Search for Steric-Electron and Topochemical Principles for Complete Fully-Protective Chemically Synthesised Vaccine Development. PLoS ONE, 2015, 10, e0123249.	2.5	25
60	Bacterial Genotoxins Promote Inside-Out Integrin \hat{I}^21 Activation, Formation of Focal Adhesion Complexes and Cell Spreading. PLoS ONE, 2015, 10, e0124119.	2.5	13
61	Recent advances in the development of a chemically synthesised anti-malarial vaccine. Expert Opinion on Biological Therapy, 2015, 15, 1567-1581.	3.1	13
62	The DNA load of six high-risk human papillomavirus types and its association with cervical lesions. BMC Cancer, 2015, 15, 100.	2.6	36
63	Mce4F Mycobacterium tuberculosis protein peptides can inhibit invasion of human cell lines. Pathogens and Disease, 2015, 73, .	2.0	17
64	Using the PfEMP1 Head Structure Binding Motif to Deal a Blow at Severe Malaria. PLoS ONE, 2014, 9, e88420.	2.5	8
65	Characterising a Microsatellite for DRB Typing in Aotus vociferans and Aotus nancymaae (Platyrrhini). PLoS ONE, 2014, 9, e96973.	2.5	15
66	Cationic Peptides Harboring Antibiotic Capacity is Selective for Leishmania Panamensis and Leishmania Major. Journal of Microbial & Biochemical Technology, 2014, 06, .	0.2	3
67	Gauche+ side-chain orientation as a key factor in the search for an immunogenic peptide mixture leading to a complete fully protective vaccine. Vaccine, 2014, 32, 2117-2126.	3.8	20
68	Plasmodium falciparum rhoptry neck protein 5 peptides bind to human red blood cells and inhibit parasite invasion. Peptides, 2014, 53, 210-217.	2.4	9
69	Specific Interaction between <i><scp>M</scp>ycobacterium tuberculosis</i> Lipoproteinâ€derived Peptides and Target Cells Inhibits Mycobacterial Entry <i>In Vitro</i> . Chemical Biology and Drug Design, 2014, 84, 626-641.	3.2	16
70	Protecting capacity against malaria of chemically defined tetramer forms based on the Plasmodium falciparum apical sushi protein as potential vaccine components. Biochemical and Biophysical Research Communications, 2014, 451, 15-23.	2.1	5
71	Persistence, clearance and reinfection regarding six high risk human papillomavirus types in Colombian women: a follow-up study. BMC Infectious Diseases, 2014, 14, 395.	2.9	18
72	Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia. BMC Cancer, 2014, 14, 451.	2.6	14

#	Article	IF	CITATIONS
73	Functional, biochemical and 3D studies of <i>Mycobacterium tuberculosis</i> protein peptides for an effective anti-tuberculosis vaccine. Critical Reviews in Microbiology, 2014, 40, 117-145.	6.1	14
74	Towards a Poly-Functional Synthetic-Antimalarial Vaccine: Incorporating Non-Natural Elements into Artificially-Made Peptides for Mimicking Functional Pathogen Ligand Structures Representing New Site-Directed Vaccine Components. Current Immunology Reviews, 2014, 9, 261-275.	1.2	0
75	Rv1268c protein peptide inhibiting Mycobacterium tuberculosis H37Rv entry to target cells. Bioorganic and Medicinal Chemistry, 2013, 21, 6650-6656.	3.0	6
76	Redefining an epitope of a malaria vaccine candidate, with antibodies against the N-terminal MSA-2 antigen of Plasmodium harboring non-natural peptide bonds. Amino Acids, 2013, 45, 913-935.	2.7	3
77	Classical Molecular Tests Using Urine Samples as a Potential Screening Tool for Human Papillomavirus Detection in Human Immunodeficiency Virus-Infected Women. Journal of Clinical Microbiology, 2013, 51, 3688-3693.	3.9	8
78	The GPI-anchored 6-Cys Protein Pv12 is Present in Detergent-resistant Microdomains of Plasmodium vivax Blood Stage Schizonts. Protist, 2013, 164, 37-48.	1.5	19
79	Rh1 high activity binding peptides inhibit high percentages of Plasmodium falciparum FVO strain invasion. Vaccine, 2013, 31, 1830-1837.	3.8	8
80	Human Papillomavirus Detection from Human Immunodeficiency Virus-Infected Colombian Women's Paired Urine and Cervical Samples. PLoS ONE, 2013, 8, e56509.	2.5	13
81	Identification and Diversity of Killer Cell Ig-Like Receptors in Aotus vociferans, a New World Monkey. PLoS ONE, 2013, 8, e79731.	2.5	9
82	The role of Mycobacterium tuberculosis Rv3166c protein-derived high-activity binding peptides in inhibiting invasion of human cell lines. Protein Engineering, Design and Selection, 2012, 25, 235-242.	2.1	8
83	Towards the development of a fully protectivePlasmodium falciparumantimalarial vaccine. Expert Review of Vaccines, 2012, 11, 1057-1070.	4.4	11
84	A single amino acid change in the Plasmodium falciparum RH5 (PfRH5) human RBC binding sequence modifies its structure and determines species-specific binding activity. Vaccine, 2012, 30, 637-646.	3.8	17
85	The diagnostic performance of classical molecular tests used for detecting human papillomavirus. Journal of Virological Methods, 2012, 185, 32-38.	2.1	15
86	The role of amino acid electron-donor/acceptor atoms in host-cell binding peptides is associated with their 3D structure and HLA-binding capacity in sterile malarial immunity induction. Biochemical and Biophysical Research Communications, 2012, 417, 938-944.	2.1	4
87	Steric–electronic effects in malarial peptides inducing sterile immunity. Biochemical and Biophysical Research Communications, 2012, 423, 857-862.	2.1	8
88	The high immunogenicity induced by modified sporozoites' malarial peptides depends on their phi (ï•) and psi (ï`) angles. Biochemical and Biophysical Research Communications, 2012, 429, 81-86.	2.1	13
89	Phi (Î ¦ ) and psi (Î [·]) angles involved in malarial peptide bonds determine sterile protective immunity. Biochemical and Biophysical Research Communications, 2012, 429, 75-80.	2.1	17
90	Mycobacterium tuberculosis surface protein Rv0227c contains high activity binding peptides which inhibit cell invasion. Peptides, 2012, 38, 208-216.	2.4	9

#	Article	IF	CITATIONS
91	Peptides derived from Mycobacterium tuberculosis Rv2301 protein are involved in invasion to human epithelial cells and macrophages. Amino Acids, 2012, 42, 2067-2077.	2.7	12
92	Decreasing the configurational entropy and the hydrophobicity of EBV-derived peptide 11389 increased its antigenicity, immunogenicity and its ability of inducing IL-6. Amino Acids, 2012, 42, 2165-2175.	2.7	1
93	Protective immunity provided by a new modified SERA protein peptide: its immunogenetic characteristics and correlation with 3D structure. Amino Acids, 2012, 43, 183-194.	2.7	6
94	Binding activity, structure, and immunogenicity of synthetic peptides derived from Plasmodium falciparum CelTOS and TRSP proteins. Amino Acids, 2012, 43, 365-378.	2.7	7
95	Structural and Immunological Principles Leading to Chemically Synthesized, Multiantigenic, Multistage, Minimal Subunit-Based Vaccine Development. Chemical Reviews, 2011, 111, 3459-3507.	47.7	93
96	Frequency of Human Papillomavirus Infection, Coinfection, and Association with Different Risk Factors in Colombia. Annals of Epidemiology, 2011, 21, 204-213.	1.9	22
97	Characterisation and comparative analysis of MHC-DPA1 exon 2 in the owl monkey (Aotus nancymaae). Gene, 2011, 470, 37-45.	2.2	9
98	Identification of the Plasmodium falciparum rhoptry neck protein 5 (PfRON5). Gene, 2011, 474, 22-28.	2.2	19
99	Electrostatic potential as a tool to understand interactions between malaria vaccine candidate peptides and MHC II molecules. Biochemical and Biophysical Research Communications, 2011, 410, 410-415.	2.1	1
100	3D structure and immunogenicity of Plasmodium falciparum sporozoite induced associated protein peptides as components of fully-protective anti-malarial vaccine. Biochemical and Biophysical Research Communications, 2011, 416, 349-355.	2.1	7
101	The Mycobacterium tuberculosis membrane protein Rv0180c: Evaluation of peptide sequences implicated in mycobacterial invasion of two human cell lines. Peptides, 2011, 32, 1-10.	2.4	17
102	Biological and structural characteristics of the binding peptides from the sporozoite proteins essential for cell traversal (SPECT)-1 and -2. Peptides, 2011, 32, 154-160.	2.4	12
103	Synthetic peptides from two Pf sporozoite invasion-associated proteins specifically interact with HeLa and HepG2 cells. Peptides, 2011, 32, 1902-1908.	2.4	10
104	Detection by PCR of human papillomavirus in Colombia: Comparison of GP5+/6+ and MY09/11 primer sets. Journal of Virological Methods, 2011, 178, 68-74.	2.1	35
105	Distribution Patterns of Infection with Multiple Types of Human Papillomaviruses and Their Association with Risk Factors. PLoS ONE, 2011, 6, e14705.	2.5	42
106	A New Approach to Obtaining <i>N</i> ^α â€ŧâ€Bocâ€Amino Acid Aldehydes from Asparagine and Glutamine for Reduced Amide Pseudopeptide Solidâ€Phase Synthesis. Chemical Biology and Drug Design, 2011, 78, 603-611.	3.2	2
107	Protection against malaria is conferred by passive transferring rabbit F(ab)2′ antibody fragments, induced by Plasmodium falciparum MSP-1 site-directed designed pseudopeptide-BSA conjugates assessed in a rodent model. Molecular Immunology, 2011, 48, 657-669.	2.2	1
108	NClassG+: A classifier for non-classically secreted Gram-positive bacterial proteins. BMC Bioinformatics, 2011, 12, 21.	2.6	28

#	Article	IF	CITATIONS
109	Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. European Journal of Pharmaceutical Sciences, 2011, 44, 32-40.	4.0	48
110	Molecular modeling and in silico characterization of Mycobacterium tuberculosis TlyA: Possible misannotation of this tubercle bacilli-hemolysin. BMC Structural Biology, 2011, 11, 16.	2.3	28
111	Identification, characterization and antigenicity of the Plasmodium vivax rhoptry neck protein 1 (PvRON1). Malaria Journal, 2011, 10, 314.	2.3	19
112	Functional, Immunological and Three-Dimensional Analysis of Chemically Synthesised Sporozoite Peptides as Components of a Fully-Effective Antimalarial Vaccine. Current Medicinal Chemistry, 2011, 18, 4470-4502.	2.4	25
113	Anti-Group A Streptococcal Vaccine Epitope. Journal of Biological Chemistry, 2011, 286, 6989-6998.	3.4	25
114	Identification of Plasmodium vivax Proteins with Potential Role in Invasion Using Sequence Redundancy Reduction and Profile Hidden Markov Models. PLoS ONE, 2011, 6, e25189.	2.5	10
115	Quantum Chemical Analysis of MHC-Peptide Interactions for Vaccine Design. Mini-Reviews in Medicinal Chemistry, 2010, 10, 746-758.	2.4	18
116	Fine mapping of Plasmodium falciparum ribosomal phosphoprotein PfPO revealed sequences with highly specific binding activity to human red blood cells. Journal of Molecular Medicine, 2010, 88, 61-74.	3.9	3
117	α-Helix peptides designed from EBV-gH protein display higher antigenicity and induction of monocyte apoptosis than the native peptide. Amino Acids, 2010, 39, 1507-1519.	2.7	0
118	Atomic fidelity of subunit-based chemically-synthesized antimalarial vaccine components. Progress in Biophysics and Molecular Biology, 2010, 102, 38-44.	2.9	14
119	Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: Potential TB vaccine candidate antigen. BMC Microbiology, 2010, 10, 109.	3.3	22
120	Conserved regions from <i>Plasmodium falciparum</i> MSP11 specifically interact with host cells and have a potential role during merozoite invasion of red blood cells. Journal of Cellular Biochemistry, 2010, 110, 882-892.	2.6	2
121	3D Analysis of the TCR/pMHCII Complex Formation in Monkeys Vaccinated with the First Peptide Inducing Sterilizing Immunity against Human Malaria. PLoS ONE, 2010, 5, e9771.	2.5	25
122	Peptides from the Mycobacterium tuberculosis Rv1980c protein involved in human cell infection: insights into new synthetic subunit vaccine candidates. Biological Chemistry, 2010, 391, 207-217.	2.5	8
123	Computational Prediction and Experimental Assessment of Secreted/Surface Proteins from Mycobacterium tuberculosis H37Rv. PLoS Computational Biology, 2010, 6, e1000824.	3.2	45
124	Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides. Drug Delivery, 2010, 17, 490-499.	5.7	16
125	Well-Defined Regions of the <i>Plasmodium falciparum</i> Reticulocyte Binding Protein Homologue 4 Mediate Interaction with Red Blood Cell Membrane. Journal of Medicinal Chemistry, 2010, 53, 811-821.	6.4	7
126	Atomic evidence that modification of H-bonds established with amino acids critical for host-cell binding induces sterile immunity against malaria. Biochemical and Biophysical Research Communications, 2010, 394, 529-535.	2.1	17

#	Article	IF	CITATIONS
127	Conserved high activity binding peptides from the Plasmodium falciparum Pf34 rhoptry protein inhibit merozoites in vitro invasion of red blood cells. Peptides, 2010, 31, 1987-1994.	2.4	13
128	Conserved regions of the Plasmodium falciparum rhoptry-associated protein 3 mediate specific host-pathogen interactions during invasion of red blood cells. Peptides, 2010, 31, 2165-2172.	2.4	4
129	Sequences of the Plasmodium falciparum cytoadherence-linked asexual protein 9 implicated in malaria parasite invasion to erythrocytes. Vaccine, 2010, 28, 2653-2663.	3.8	7
130	3D structure determination of STARP peptides implicated in P. falciparum invasion of hepatic cells. Vaccine, 2010, 28, 4989-4996.	3.8	8
131	Conserved High Activity Binding Peptides are Involved in Adhesion of Two Detergent-Resistant Membrane-Associated Merozoite Proteins to Red Blood Cells during Invasion. Journal of Medicinal Chemistry, 2010, 53, 3907-3918.	6.4	12
132	Development of Designed Site-Directed Pseudopeptide-Peptido-Mimetic Immunogens as Novel Minimal Subunit-Vaccine Candidates for Malaria. Molecules, 2010, 15, 8856-8889.	3.8	6
133	Validating subcellular localization prediction tools with mycobacterial proteins. BMC Bioinformatics, 2009, 10, 134.	2.6	31
134	Prevalence of infection with high-risk human papillomavirus in women in Colombia. Clinical Microbiology and Infection, 2009, 15, 100-102.	6.0	11
135	Structural characteristics of immunogenic liver-stage antigens derived from P. falciparum malarial proteins. Biochemical and Biophysical Research Communications, 2009, 384, 455-460.	2.1	9
136	Identification of conserved erythrocyte binding regions in members of the Plasmodium falciparum Cys6 lipid raft-associated protein family. Vaccine, 2009, 27, 3953-3962.	3.8	28
137	Synthetic peptides from conserved regions of the Plasmodium falciparum early transcribed membrane and ring exported proteins bind specifically to red blood cell proteins. Vaccine, 2009, 27, 6877-6886.	3.8	8
138	Passive transfer of Plasmodium falciparum MSP-2 pseudopeptide-induced antibodies efficiently controlled parasitemia in Plasmodium berghei-infected mice. Peptides, 2009, 30, 330-342.	2.4	3
139	A C-terminal cationic fragment derived from an arginine-rich peptide exhibits in vitro antibacterial and anti-plasmodial activities governed by its secondary structure properties. Peptides, 2009, 30, 2150-2160.	2.4	8
140	A Maurer's cleft-associated Plasmodium falciparum membrane-associated histidine-rich protein peptide specifically interacts with the erythrocyte membrane. Biochemical and Biophysical Research Communications, 2009, 380, 122-126.	2.1	6
141	Prevalence of HPV-DNA and Anti-HPV Antibodies in Women From Girardot, Colombia. Sexually Transmitted Diseases, 2009, 36, 290-296.	1.7	7
142	Nucleic-acid-binding properties of the C2-L1Tc nucleic acid chaperone encoded by L1Tc retrotransposon. Biochemical Journal, 2009, 424, 479-490.	3.7	10
143	Variations in the Electrostatic Landscape of Class II Human Leukocyte Antigen Molecule Induced by Modifications in the Myelin Basic Protein Peptide: A Theoretical Approach. PLoS ONE, 2009, 4, e4164.	2.5	6
144	Novel Chimeric Peptide Inhibits Protein Kinase C and Induces Apoptosis in Human Immune Cells. International Journal of Peptide Research and Therapeutics, 2008, 14, 64-74.	1.9	4

#	Article	IF	CITATIONS
145	Characterizing the <i>Mycobacterium tuberculosis</i> Rv2707 protein and determining its sequences which specifically bind to two human cell lines. Protein Science, 2008, 17, 342-351.	7.6	14
146	Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clinical and Experimental Immunology, 2008, 84, 122-128.	2.6	47
147	Strategies for developing multiâ€epitope, subunitâ€based, chemically synthesized antiâ€malarial vaccines. Journal of Cellular and Molecular Medicine, 2008, 12, 1915-1935.	3.6	30
148	Identification of <i>Plasmodium falciparum</i> RhopH3 protein peptides that specifically bind to erythrocytes and inhibit merozoite invasion. Protein Science, 2008, 17, 1719-1730.	7.6	15
149	Characterization of <i>Plasmodium falciparum</i> integral membrane protein Pf25â€IMP and identification of its red blood cell binding sequences inhibiting merozoite invasion in vitro. Protein Science, 2008, 17, 1494-1504.	7.6	16
150	Emerging Rules for Subunit-Based, Multiantigenic, Multistage Chemically Synthesized Vaccines. Accounts of Chemical Research, 2008, 41, 377-386.	15.6	112
151	Intimate Molecular Interactions of <i>P. falciparum</i> Merozoite Proteins Involved in Invasion of Red Blood Cells and Their Implications for Vaccine Design. Chemical Reviews, 2008, 108, 3656-3705.	47.7	94
152	Studies of Plasmodium falciparum rhoptry-associated membrane antigen (RAMA) protein peptides specifically binding to human RBC. Vaccine, 2008, 26, 853-862.	3.8	17
153	Peptides derived from the Mycobacterium tuberculosis Rv1490 surface protein implicated in inhibition of epithelial cell entry: Potential vaccine candidates?. Vaccine, 2008, 26, 4387-4395.	3.8	10
154	Immunological profile of a Plasmodium vivax AMA-1 N-terminus peptide-carbon nanotube conjugate in an infected Plasmodium berghei mouse model. Vaccine, 2008, 26, 5864-5873.	3.8	60
155	Structural and immunological analysis of circumsporozoite protein peptides: A further step in the identification of potential components of a minimal subunit-based, chemically synthesised antimalarial vaccine. Vaccine, 2008, 26, 6908-6918.	3.8	19
156	Structural characterisation of sporozoite components for a multistage, multi-epitope, anti-malarial vaccine. International Journal of Biochemistry and Cell Biology, 2008, 40, 543-557.	2.8	22
157	High affinity interactions between red blood cell receptors and synthetic Plasmodium thrombospondin-related apical merozoite protein (PTRAMP) peptides. Biochimie, 2008, 90, 802-810.	2.6	5
158	Identification of peptides with high red blood cell and hepatocyte binding activity in the Plasmodium falciparum multi-stage invasion proteins: PfSPATR and MCP-1. Biochimie, 2008, 90, 1750-1759.	2.6	7
159	Î ³ -Irradiation effects on biopharmaceutical properties of PLGA microspheres loaded with SPf66 synthetic vaccine. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 519-526.	4.3	41
160	HLA-DR allele reading register shifting is associated with immunity induced by SERA peptide analogues. Biochemical and Biophysical Research Communications, 2008, 372, 114-120.	2.1	2
161	Functional characterization of Mycobacterium tuberculosis Rv2969c membrane protein. Biochemical and Biophysical Research Communications, 2008, 372, 935-940.	2.1	11
162	A non-variable L1-peptide displays high sensitivity and specificity for detecting women having human papillomavirus-associated cervical lesions. Peptides, 2008, 29, 957-962.	2.4	1

#	Article	IF	CITATIONS
163	Specificity of L1 Peptides versus Virus-Like Particles for Detection of Human Papillomavirus-Positive Cervical Lesions in Females Attending Engativa Hospital, Bogota, Colombia. Journal of Clinical Microbiology, 2008, 46, 3714-3720.	3.9	5
164	Structural modifications to a high-activity binding peptide located within the PfEMP1 NTS domain induce protection against P. falciparum malaria in Aotus monkeys. Biological Chemistry, 2007, 388, 25-36.	2.5	10
165	Characterisation of Plasmodium falciparum RESA-like protein peptides that bind specifically to erythrocytes and inhibit invasion. Biological Chemistry, 2007, 388, 15-24.	2.5	4
166	Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization. Vaccine, 2007, 25, 4487-4501.	3.8	15
167	Flow cytometric analysis on cross-reactivity of human-specific CD monoclonal antibodies with splenocytes of Aotus nancymaae, a non-human primate model for biomedical research. Veterinary Immunology and Immunopathology, 2007, 119, 14-20.	1.2	9
168	Immunological and structural characterization of an epitope from the Trypanosoma cruzi KMP-11 protein. Peptides, 2007, 28, 1520-1526.	2.4	15
169	Antibodies induced by Plasmodium falciparum merozoite surface antigen-2-designed pseudopeptides possess neutralizing properties of the in vitro malarial infection. Peptides, 2007, 28, 1954-1965.	2.4	5
170	BTM-P1 polycationic peptide biological activity and 3D-dimensional structure. Biochemical and Biophysical Research Communications, 2007, 353, 908-914.	2.1	21
171	Functional, structural, and immunological compartmentalisation of malaria invasive proteins. Biochemical and Biophysical Research Communications, 2007, 354, 363-371.	2.1	22
172	Monosaccharides modulate HCV E2 protein-derived peptide biological properties. Biochemical and Biophysical Research Communications, 2007, 355, 409-418.	2.1	5
173	A pre-PEXEL histidine-rich protein II erythrocyte binding peptide as a new way for anti-malarial vaccine development. Biochemical and Biophysical Research Communications, 2007, 360, 149-155.	2.1	5
174	Identifying Merozoite Surface Protein 4 and Merozoite Surface Protein 7 <i>Plasmodium falciparum</i> Protein Family Members Specifically Binding to Human Erythrocytes Suggests a New Malarial Parasite-Redundant Survival Mechanism. Journal of Medicinal Chemistry, 2007, 50, 5665-5675.	6.4	18
175	Immune response in mice and cattle after immunization with a Boophilus microplus DNA vaccine containing bm86 gene. Veterinary Parasitology, 2007, 144, 138-145.	1.8	9
176	A rational strategy for a malarial vaccine development. Microbes and Infection, 2007, 9, 751-760.	1.9	7
177	Wave function analysis of MHC–peptide interactions. Journal of Molecular Graphics and Modelling, 2007, 25, 605-615.	2.4	5
178	The <i>Mycobacterium tuberculosis</i> membrane protein Rv2560â€fâ^â€fbiochemical and functional studies. FEBS Journal, 2007, 274, 6352-6364.	4.7	13
179	Developmental Biology of Sporozoite-Host Interactions in Plasmodium falciparum Malaria: Implications for Vaccine Design. Clinical Microbiology Reviews, 2006, 19, 686-707.	13.6	55
180	Plasmodium falciparum TryThrA antigen synthetic peptides block in vitro merozoite invasion to erythrocytes. Biochemical and Biophysical Research Communications, 2006, 339, 888-896.	2.1	18

#	Article	IF	CITATIONS
181	Determining the 3D structure of human ASC2 protein involved in apoptosis and inflammation. Biochemical and Biophysical Research Communications, 2006, 340, 860-864.	2.1	11
182	Protective cellular immunity against P. falciparum malaria merozoites is associated with a different P7 and P8 residue orientation in the MHC–peptide–TCR complex. Biochimie, 2006, 88, 219-230.	2.6	7
183	High non-protective, long-lasting antibody levels inÂmalaria are associated with haplotype shifting inÂMHC–peptide–TCR complex formation: aÂnew mechanism forÂimmune evasion. Biochimie, 2006, 88, 775-784.	2.6	10
184	Synthetic peptides from PlasmodiumÂfalciparum apical membrane antigen 1 (AMA-1) specifically interacting with human hepatocytes. Biochimie, 2006, 88, 1447-1455.	2.6	9
185	A theoretical analysis ofÂHLA-DRβ1*0301–CLIP complex using theÂfirst threeÂmultipolar moments ofÂtheÂelectrostatic field. Biochimie, 2006, 88, 1307-1311.	2.6	5
186	Plasmodium falciparum merozoite surface protein 6 (MSP-6) derived peptides bind erythrocytes and partially inhibit parasite invasion. Peptides, 2006, 27, 1685-1692.	2.4	14
187	Reference strand conformational analysis (RSCA) is a valuable tool in identifying MHC-DRB sequences in three species of Aotus monkeys. Immunogenetics, 2006, 58, 590-597.	2.4	15
188	Owl monkey MHC-DRB exon 2 reveals high similarity with several HLA-DRB lineages. Immunogenetics, 2006, 58, 542-558.	2.4	68
189	Comparative molecular and three-dimensional analysis of the peptide–MHC II binding region in both human and Aotus MHC-DRB molecules confirms their usefulness in antimalarial vaccine development. Immunogenetics, 2006, 58, 598-606.	2.4	9
190	Toxoplasma gondii: Immunogenicity and protection by P30 peptides in a murine model. Experimental Parasitology, 2006, 114, 62-65.	1.2	51
191	What is Hidden Behind Peptide Bond Restriction and α-Carbon Asymmetry of Conserved Antigens? Peptide Bond Isosters and Chirally Transformed Pseudopeptides as Novel Elements for Synthetic Vaccines and Therapeutic Agents Against Malaria. Current Organic Chemistry, 2006, 10, 433-456.	1.6	5
192	Major Histocompatibility Complex and T Cell Interactions of a Universal T Cell Epitope from Plasmodium falciparum Circumsporozoite Protein. Journal of Biological Chemistry, 2006, 281, 14907-14917.	3.4	30
193	Peptide Vaccines for Malaria. , 2006, , 515-526.		4
194	Identifying Plasmodium falciparum cytoadherence-linked asexual protein 3 (CLAG 3) sequences that specifically bind to C32 cells and erythrocytes. Protein Science, 2005, 14, 504-513.	7.6	16
195	Mycobacterium tuberculosisRv2536 protein implicated in specific binding to human cell lines. Protein Science, 2005, 14, 2236-2245.	7.6	17
196	Identifying putativeMycobacterium tuberculosisRv2004c protein sequences that bind specifically to U937 macrophages and A549 epithelial cells. Protein Science, 2005, 14, 2767-2780.	7.6	23
197	A comparative study of MHC Class-II HLA-DRβ1*0401-Col II and HLA-DRβ1*0101-HA complexes: a theoretical point of view. Journal of Structural Biology, 2005, 149, 38-52.	2.8	13
198	Identification of five different IGHV gene families in owl monkeys (Aotus nancymaae). Tissue Antigens, 2005, 66, 640-649.	1.0	7

#	Article	IF	CITATIONS
199	Herpesvirus saimiri immortalization of Aotus T lymphocytes specific for an immunogenically modified peptide of Plasmodium falciparum merozoite surface antigen 2. Immunology and Cell Biology, 2005, 83, 67-74.	2.3	7
200	MHC class I genes in the owl monkey: mosaic organisation, convergence and loci diversity. Immunogenetics, 2005, 56, 818-832.	2.4	18
201	The T-cell receptor in primates: identifying and sequencing new owl monkey TRBV gene sub-groups. Immunogenetics, 2005, 57, 42-52.	2.4	19
202	Structural and functional characterisation of the Toll like receptor 9 of Aotus nancymaae, a non-human primate model for malaria vaccine development. Immunogenetics, 2005, 57, 283-288.	2.4	6
203	Based on HLA-DRβ1* Allele Binding Specificities, Striking Differences in Distance and TCR Contacting Residue Orientation can be Observed in Modified Protection-Inducing Malarial Synthetic Peptides. Current Medicinal Chemistry, 2005, 12, 2849-2865.	2.4	11
204	Identification of Three gp350/220 Regions Involved in Epstein-Barr Virus Invasion of Host Cells. Journal of Biological Chemistry, 2005, 280, 35598-35605.	3.4	27
205	P. falciparum pro-histoaspartic protease (proHAP) protein peptides bind specifically to erythrocytes and inhibit the invasion process in vitro. Biological Chemistry, 2005, 386, 361-7.	2.5	2
206	Peptides Inducing Short-Lived Antibody Responses againstPlasmodium falciparumMalaria Have Shorter Structures and Are Read in a Different MHC II Functional Registerâ€. Biochemistry, 2005, 44, 6745-6754.	2.5	23
207	Elongating modified conserved peptides eliminates their immunogenicity and protective efficacy against P. falciparum malaria. Journal of Structural Biology, 2005, 150, 245-258.	2.8	2
208	Protection against malaria induced by chirally modified Plasmodium falciparum's MSP-142 pseudopeptides. Biochemical and Biophysical Research Communications, 2005, 329, 1053-1066.	2.1	7
209	Allele effects in MHC–peptide interactions: A theoretical analysis of HLA-DRβ1*0101-HA and HLA-DRβ1*0401-HA complexes. Biochemical and Biophysical Research Communications, 2005, 330, 1162-1167.	2.1	19
210	Two L1-peptides are excellent tools for serological detection of HPV-associated cervical carcinoma lesions. Biochemical and Biophysical Research Communications, 2005, 332, 224-232.	2.1	10
211	Characterising Mycobacterium tuberculosis Rv1510c protein and determining its sequences that specifically bind to two target cell lines. Biochemical and Biophysical Research Communications, 2005, 332, 771-781.	2.1	18
212	Identification and characterisation of the Plasmodium vivax rhoptry-associated protein 2. Biochemical and Biophysical Research Communications, 2005, 337, 853-859.	2.1	27
213	Fitting modified HRP-I peptide analogue 3D structure into HLA-DR molecules induces protection against Plasmodium falciparum malaria. International Journal of Biochemistry and Cell Biology, 2005, 37, 336-349.	2.8	6
214	Identifying Plasmodium falciparum merozoite surface protein-10 human erythrocyte specific binding regions. Biochimie, 2005, 87, 461-472.	2.6	21
215	Amino terminal peptides from the Plasmodium falciparum EBA-181/JESEBL protein bind specifically to erythrocytes and inhibit in vitro merozoite invasion. Biochimie, 2005, 87, 425-436.	2.6	9
216	A B-lymphocyte binding peptide from BNRF1 induced antibodies inhibiting EBV-invasion of B-lymphocytes. Biochimie, 2005, 87, 985-992.	2.6	1

#	Article	IF	CITATIONS
217	Peptides from the Plasmodium falciparum STEVOR putative protein bind with high affinity to normal human red blood cells. Peptides, 2005, 26, 1133-1143.	2.4	18
218	Evidence supporting the hypothesis that specifically modifying a malaria peptide to fit into HLA-DRÎ ² 1*03 molecules induces antibody production and protection. Vaccine, 2005, 23, 1579-1587.	3.8	10
219	Specific erythrocyte binding capacity and biological activity of Plasmodium falciparum erythrocyte binding ligand 1 (EBL-1)-derived peptides. Protein Science, 2005, 14, 464-473.	7.6	14
220	IdentifyingPlasmodium falciparummerozoite surface antigen 3 (MSP3) protein peptides that bind specifically to erythrocytes and inhibit merozoite invasion. Protein Science, 2005, 14, 1778-1786.	7.6	20
221	Comparative analysis of CD45 proteins in primate context: owl monkeys vs humans. Tissue Antigens, 2004, 64, 165-172.	1.0	5
222	Isolation and identification of mycobacteria in New World primates maintained in captivity. Veterinary Microbiology, 2004, 98, 285-295.	1.9	33
223	Enhancing Immunogenicity and Reducing Dose of Microparticulated Synthetic Vaccines: Single Intradermal Administration. Pharmaceutical Research, 2004, 21, 121-126.	3.5	28
224	Liver stage antigen 3 Plasmodium falciparum peptides specifically interacting with HepG2 cells. Journal of Molecular Medicine, 2004, 82, 600-11.	3.9	9
225	Identifying and structurally characterizing CD1b in Aotus nancymaae owl monkeys. Immunogenetics, 2004, 56, 480-489.	2.4	8
226	Structural Modifications Enable Conserved Peptides to Fit into MHC Molecules thus Inducing Protection against Malaria. ChemBioChem, 2004, 5, 1588-1593.	2.6	21
227	Orientating Peptide Residues and Increasing the Distance between Pockets to Enable Fitting into MHCâ ^{~^} TCR Complex Determine Protection against Malaria. Biochemistry, 2004, 43, 6545-6553.	2.5	17
228	Identification of Plasmodium falciparum reticulocyte binding protein RBP-2 homologue a and b (PfRBP-2-Ha and -Hb) sequences that specifically bind to erythrocytes. Parasitology International, 2004, 53, 77-88.	1.3	16
229	Quantifying Aotus monkey cytokines by real-time quantitative RT-PCR. Cytokine, 2004, 27, 129-133.	3.2	10
230	Plasmodium falciparum: red blood cell binding studies using peptides derived from rhoptry-associated protein 2 (RAP2). Biochimie, 2004, 86, 1-6.	2.6	16
231	MAEBL Plasmodium falciparum protein peptides bind specifically to erythrocytes and inhibit in vitro merozoite invasion. Biochemical and Biophysical Research Communications, 2004, 315, 319-329.	2.1	16
232	Shortening and modifying the 1513 MSP-1 peptide's α-helical region induces protection against malaria. Biochemical and Biophysical Research Communications, 2004, 315, 418-427.	2.1	26
233	Modifying RESA protein peptide 6671 to fit into HLA-DRÎ ² 1* pockets induces protection against malaria. Biochemical and Biophysical Research Communications, 2004, 315, 1154-1164.	2.1	22
234	Identifying gp85-regions involved in Epstein–Barr virus binding to B-lymphocytes. Biochemical and Biophysical Research Communications, 2004, 319, 221-229.	2.1	13

#	Article	IF	CITATIONS
235	Identifying Plasmodium falciparum EBA-175 homologue sequences that specifically bind to human erythrocytes. Biochemical and Biophysical Research Communications, 2004, 321, 835-844.	2.1	7
236	Changing ABRA protein peptide to fit into the HLA-DRÎ ² 1*0301 molecule renders it protection-inducing. Biochemical and Biophysical Research Communications, 2004, 322, 119-125.	2.1	15
237	Quantum chemical analysis explains hemagglutinin peptide–MHC Class II molecule HLA-DRβ1*0101 interactions. Biochemical and Biophysical Research Communications, 2004, 323, 1265-1277.	2.1	17
238	Specific erythrocyte binding capacity and biological activity of Plasmodium falciparum-derived rhoptry-associated protein 1 peptides. Vaccine, 2004, 22, 1054-1062.	3.8	14
239	Induction and displacement of an α helix in the 6725 SERA peptide analogue confers protection against P. falciparum malaria. Vaccine, 2004, 22, 1281-1289.	3.8	9
240	Sporozoite and Liver Stage Antigen Plasmodium falciparum peptides bind specifically to human hepatocytes. Vaccine, 2004, 22, 1150-1156.	3.8	13
241	Characterization of a reduced peptide bond analogue of a promiscuous CD4 T cell epitope derived from the Plasmodium falciparum malaria vaccine candidate merozoite surface protein 1. Molecular Immunology, 2004, 41, 775-784.	2.2	12
242	Mapping the anatomy of a Plasmodium falciparum MSP-1 epitope using pseudopeptide-induced mono- and polyclonal antibodies and CD and NMR conformation analysis. Journal of Structural Biology, 2004, 148, 110-122.	2.8	11
243	Human papillomavirus type 16 and 18 L1 protein peptide binding to VERO and HeLa cells inhibits their VLPs binding. International Journal of Cancer, 2003, 107, 416-424.	5.1	13
244	T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/lpr mice. European Journal of Immunology, 2003, 33, 287-296.	2.9	127
245	Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. International Journal of Pharmaceutics, 2003, 260, 273-282.	5.2	43
246	α1 and α2 domains of Aotus MHC Class I and Catarrhini MHC Class Ia share similar characteristics. Tissue Antigens, 2003, 61, 362-373.	1.0	13
247	Proliferative response of peripheral blood lymphocytes to mitogens in the owl monkey Aotus nancymae. Journal of Medical Primatology, 2003, 32, 31-38.	0.6	9
248	Characterizing cellular immune response to kinetoplastid membrane protein-11 (KMP-11) during Leishmania (Viannia) panamensis infection using dendritic cells (DCs) as antigen presenting cells (APCs). Parasite Immunology, 2003, 25, 199-209.	1.5	15
249	Characterizing T-cell receptor gamma-variable gene in Aotus nancymaae owl monkey peripheral blood. Tissue Antigens, 2003, 62, 472-482.	1.0	19
250	Modified merozoite surface protein-1 peptides with short alpha helical regions are associated with inducing protection against malaria. FEBS Journal, 2003, 270, 3946-3952.	0.2	28
251	Alpha helix shortening in 1522 MSP-1 conserved peptide analogs is associated with immunogenicity and protection against P. falciparum malaria. Proteins: Structure, Function and Bioinformatics, 2003, 50, 400-409.	2.6	28
252	Electronic Energy and Multipolar Moments Characterize Amino Acid Side Chains into Chemically Related Groups. Journal of Physical Chemistry A, 2003, 107, 10090-10097.	2.5	22

#	Article	IF	CITATIONS
253	An Alpha Helix Conformationally Restricted Peptide Is Recognized by Cervical Carcinoma Patients' Sera. Journal of Medicinal Chemistry, 2003, 46, 5389-5394.	6.4	26
254	MSP-1 Malaria Pseudopeptide Analogs: Biological and Immunological Significance and Three-Dimensional Structure. Biological Chemistry, 2003, 384, 71-82.	2.5	12
255	Distorting Malaria Peptide Backbone Structure to Enable Fitting into MHC Class II Molecules Renders Modified Peptides Immunogenic and Protective. Journal of Medicinal Chemistry, 2003, 46, 2250-2253.	6.4	27
256	MHC allele-specific binding of a malaria peptide makes it become promiscuous on fitting a glycine residue into pocket 6. Biochemical and Biophysical Research Communications, 2003, 307, 148-156.	2.1	33
257	Plasmodium falciparum SERA protein peptide analogues having short helical regions induce protection against malaria. Biochimie, 2003, 85, 651-657.	2.6	14
258	Peptides of the liver stage antigen-1 (LSA-1) of Plasmodium falciparum bind to human hepatocytes. Peptides, 2003, 24, 647-657.	2.4	18
259	P. falciparum: merozoite surface protein-8 peptides bind specifically to human erythrocytes. Peptides, 2003, 24, 1015-1023.	2.4	21
260	Plasmodium falciparum normocyte binding protein (PfNBP-1) peptides bind specifically to human erythrocytes. Peptides, 2003, 24, 1007-1014.	2.4	15
261	6746 SERA peptide analogues immunogenicity and protective efficacy against malaria is associated with short α helix formation:. Peptides, 2003, 24, 999-1006.	2.4	23
262	Identification of specific Hep G2 cell binding regions in Plasmodium falciparum sporozoite–threonine–asparagine-rich protein (STARP). Vaccine, 2003, 21, 2404-2411.	3.8	9
263	Analysis of a Plasmodium falciparum EBA-175 peptide with high binding capacity to erythrocytes and their analogues using 1H NMR. Journal of Structural Biology, 2003, 141, 115-121.	2.8	30
264	Immunogenicity and Protectivity of Plasmodium falciparum EBA-175 Peptide and Its Analog Is Associated with α-Helical Region Shortening and Displacement. Biological Chemistry, 2003, 384, 1443-50.	2.5	28
265	Immunodiagnosis of Parasitic Diseases with Synthetic Peptides. Current Protein and Peptide Science, 2003, 4, 299-308.	1.4	74
266	Antigenicity of Leishmania braziliensis Histone H1 during Cutaneous Leishmaniasis: Localization of Antigenic Determinants. Vaccine Journal, 2002, 9, 808-811.	3.1	13
267	Plasmodium vivax Promiscuous T-Helper Epitopes Defined and Evaluated as Linear Peptide Chimera Immunogens. Infection and Immunity, 2002, 70, 3479-3492.	2.2	39
268	Hepatitis C virus (HCV) E1 and E2 protein regions that specifically bind to HepG2 cells. Journal of Hepatology, 2002, 36, 254-262.	3.7	40
269	Protection against experimental malaria associated with AMA-1 peptide analogue structures. FEBS Letters, 2002, 527, 95-100.	2.8	33
270	1H-NMR structures of the Plasmodium falciparum 1758 erythrocyte binding peptide analogues and protection against malaria. Life Sciences, 2002, 71, 2773-2785.	4.3	20

Manuel Elkin Me Patarroyo

#	Article	IF	CITATIONS
271	Plasmodium vivax Duffy binding protein peptides specifically bind to reticulocytes. Peptides, 2002, 23, 13-22.	2.4	37
272	Identification and polymorphism of Plasmodium vivax RBP-1 peptides which bind specifically to reticulocytes. Peptides, 2002, 23, 2265-2277.	2.4	31
273	Plasmodium vivax MSP-1 peptides have high specific binding activity to human reticulocytes. Vaccine, 2002, 20, 1331-1339.	3.8	56
274	Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine, 2002, 20, 2263-2277.	3.8	79
275	NMR structure of Plasmodium falciparum malaria peptide correlates with protective immunity. Biochimica Et Biophysica Acta - General Subjects, 2002, 1571, 27-33.	2.4	34
276	Protection against experimental P.Âfalciparum malaria is associated with short AMA-1 peptide analogue α-helical structures. Biochimie, 2002, 84, 1181-1188.	2.6	33
277	Laminin isoforms in tumor invasion, angiogenesis and metastasis. Seminars in Cancer Biology, 2002, 12, 197-207.	9.6	319
278	Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope ofPlasmodium falciparum merozoite surface protein?1 displaying dimorphic amino acid polymorphism are highly constrained. European Journal of Immunology, 2002, 32, 3667-3677.	2.9	18
279	Partial characterization of the CD45 phosphatase cDNA in the owl monkey (Aotus vociferans). American Journal of Primatology, 2002, 57, 1-11.	1.7	8
280	Sequence and expression of MHC-DPB1 molecules of the New World monkey Aotus nancymaae, a primate model for Plasmodium falciparum. Immunogenetics, 2002, 54, 251-259.	2.4	24
281	Identification, cloning, and sequencing of different cytokine genes in four species of owl monkey. Immunogenetics, 2002, 54, 645-653.	2.4	20
282	Antigenic properties of the Leishmania infantum GRP94 and mapping of linear B-cell epitopes. Immunology Letters, 2002, 80, 199-205.	2.5	22
283	Chromatographic characterization of synthetic peptides: SPf66 malaria vaccine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 766, 3-12.	2.3	13
284	Constructing a useful tool for characterizing amino acid conformers by means of quantum chemical and graph theory indices. Computers & Chemistry, 2002, 26, 667-682.	1.2	4
285	Flow cytometry, a useful tool for detecting the lethal effect of pentamidine on leishmania viannia complex promastigote forms. Pharmacological Research, 2001, 44, 281-286.	7.1	10
286	Plasmodium falciparum circumsporozoite (CS) protein peptides specifically bind to HepG2 cells. Vaccine, 2001, 19, 4487-4495.	3.8	27
287	Mapping of the antigenic determinants of the T. cruzi kinetoplastid membrane protein-11. Identification of a linear epitope specifically recognized by human Chagasic sera. Clinical and Experimental Immunology, 2001, 123, 465-471.	2.6	29
288	Synthesis, Biological, and Immunological Properties of Cyclic Peptides fromPlasmodium Falciparum Merozoite Surface Protein-1. Angewandte Chemie - International Edition, 2001, 40, 2631-2635.	13.8	29

#	Article	IF	CITATIONS
289	Structure, Immunogenicity, and Protectivity Relationship for the 1585 Malarial Peptide and Its Substitution Analogues. Angewandte Chemie - International Edition, 2001, 40, 4654-4657.	13.8	72
290	Plasmodium vivax: functional analysis of a highly conserved PvRBP-1 protein region. Molecular and Biochemical Parasitology, 2001, 117, 229-234.	1.1	20
291	T-Cell Reactivity against Streptococcal Antigens in the Periphery Mirrors Reactivity of Heart-Infiltrating T Lymphocytes in Rheumatic Heart Disease Patients. Infection and Immunity, 2001, 69, 5345-5351.	2.2	93
292	Functional and Structural Similarity of Vγ9VÎ′2 T Cells in Humans andAotusMonkeys, a Primate Infection Model forPlasmodium falciparumMalaria. Journal of Immunology, 2001, 167, 6421-6430.	0.8	40
293	Synthesis, Biological, and Immunological Properties of Cyclic Peptides from Plasmodium Falciparum Merozoite Surface Protein-1 This work was supported by a long-term fellowship of the Human Frontier Science Program Organization (HFSPO-LT 25/97) and by a Research Grant from the Roche Research Foundation Angewandte Chemie - International Edition. 2001. 40. 2631-2635.	13.8	4
294	Plasmodium falciparum: Polymorphism in Regions II and III of the Knob-Associated Histidine-Rich Protein Gene from Two Areas of Different Endemicity. Experimental Parasitology, 2000, 94, 264-268.	1.2	0
295	Plasmodium vivax: Polymorphism in the Merozoite Surface Protein 1 Gene from Wild Colombian Isolates. Experimental Parasitology, 2000, 95, 215-219.	1.2	30
296	Sequence and diversity of MHC DQA and DQB genes of the owl monkey Aotus nancymaae. Immunogenetics, 2000, 51, 528-537.	2.4	51
297	Sequence and diversity of DRB genes of Aotus nancymaae , a primate model for human malaria parasites. Immunogenetics, 2000, 51, 219-230.	2.4	77
298	A GBP 130 derived peptide from Plasmodium falciparum binds to human erythrocytes and inhibits merozoite invasion in vitro. Memorias Do Instituto Oswaldo Cruz, 2000, 95, 495-501.	1.6	12
299	Activation Pattern and Toxicity of the Cry11Bb1 Toxin of Bacillus thuringiensis Subsp. Medellin. Journal of Invertebrate Pathology, 2000, 76, 56-62.	3.2	18
300	Plasmodium falciparum: red blood cell binding studies of peptides derived from histidine-rich KAHRP-I, HRP-II and HRP-III proteins. Acta Tropica, 2000, 75, 349-359.	2.0	23
301	Plasmodium falciparum AMA-1 erythrocyte binding peptides implicate AMA-1 as erythrocyte binding protein. Vaccine, 2000, 19, 508-513.	3.8	52
302	Amino terminal peptides of the ring infected erythrocyte surface antigen of Plasmodium falciparum bind specifically to erythrocytes. Vaccine, 2000, 18, 1289-1293.	3.8	24
303	Serine repeat antigen peptides which bind specifically to red blood cells. Parasitology International, 2000, 49, 105-117.	1.3	35
304	Antigenicity of theLeishmania infantumhistones H2B and H4 during canine viscerocutaneous leishmaniasis. Clinical and Experimental Immunology, 1999, 115, 342-349.	2.6	54
305	Leishmania: Fine Mapping of the Leishmanolysin Molecule's Conserved Core Domains Involved in Binding and Internalization. Experimental Parasitology, 1999, 93, 7-22.	1.2	22
306	CD4 ⁺ T-Cell- and Gamma Interferon-Dependent Protection against Murine Malaria by Immunization with Linear Synthetic Peptides from a <i>Plasmodium yoelii</i> 17-Kilodalton Hepatocyte Erythrocyte Protein. Infection and Immunity, 1999, 67, 5604-5614.	2.2	50

#	Article	IF	CITATIONS
307	Schistosoma mansoni infection in owl monkeys (Aontus nancymai): Evidence for the early elimination of adult worms. Acta Tropica, 1998, 70, 257-267.	2.0	10
308	Genetic restriction in two conserved regions of Plasmodium falciparum EBA-175t. Molecular and Biochemical Parasitology, 1997, 85, 255-258.	1.1	3
309	Malaria vaccines. Journal of Clinical Immunology, 1996, 16, 183-189.	3.8	17
310	Genetic polymorphism of the Duffy receptor binding domain of Plasmodium vivax in Colombian wild isolates. Molecular and Biochemical Parasitology, 1996, 78, 269-272.	1.1	75
311	Identification of Plasmodium falciparum MSPâ€1 peptides able to bind to human red blood cells. Parasite Immunology, 1996, 18, 515-526.	1.5	132
312	Comparison of prevalence of anti-hepatitis C virus antibodies in differing South American populations. Journal of Medical Virology, 1996, 50, 188-192.	5.0	13
313	Mapping of the linear antigenic determinants of the Leishmania infantum Hsp70 recognized by leishmaniasis sera. Immunology Letters, 1996, 52, 73-79.	2.5	32
314	DIAGNOSIS OF CUTANEOUS TUBERCULOSIS BY POLYMERASE CHAIN REACTION USING A SPECIES-SPECIEIC GENE. International Journal of Dermatology, 1996, 35, 185-188.	1.0	53
315	Malaria vaccines. Current Opinion in Immunology, 1995, 7, 607-611.	5.5	11
316	Identification of the Leishmania infantum PO ribosomal protein epitope in canine visceral leishmaniasis. Immunology Letters, 1995, 48, 23-28.	2.5	31
317	Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis. Immunology Letters, 1995, 48, 209-214.	2.5	48
318	Constitutive αVβ3 integrin-mediated adhesion of human lymphoid B cells to vitronectin substrate. Cellular Immunology, 1995, 160, 165-172.	3.0	20
319	Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis, 1993, 103, 213-219.	0.8	58
320	Mapping of antigenic determinants of the T. cruzi HSP70 in chagasic and healthy individuals. Molecular Immunology, 1993, 30, 1115-1121.	2.2	20
321	Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet, The, 1993, 341, 705-710.	13.7	206
322	Safety and Immunogenicity of the Synthetic Malaria Vaccine SPf66 in a Large Field Trial. Journal of Infectious Diseases, 1992, 166, 139-144.	4.0	56
323	A specific T-cell receptor genotype preference in the immune response to a synthetic Plasmodium falciparum malaria vaccine. Parasite Immunology, 1992, 14, 87-94.	1.5	23
324	Determination of the immunization schedule for field trials with the synthetic malaria vaccine SPf 66. Parasite Immunology, 1992, 14, 95-109.	1.5	26

#	Article	IF	CITATIONS
325	In human malaria protective antibodies are directed mainly against the Lys-Glu ion pair within the Lys-Glu-Lys motif of the synthetic vaccine SPf 66. Parasite Immunology, 1992, 14, 111-124.	1.5	26
326	Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1–14 years. Vaccine, 1992, 10, 175-178.	3.8	65
327	The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity. Vaccine, 1992, 10, 179-184.	3.8	75
328	Regulation of hsp70 expression in Trypanosoma cruzi by temperature and growth phase. Molecular and Biochemical Parasitology, 1992, 53, 201-211.	1.1	45
329	Molecular analysis of HLA DR4-/β1 gene in malaria vaccinees. Typing and subtyping by PCR technique and oligonucleotides. Parasite Immunology, 1991, 13, 201-210.	1.5	25
330	Genetic control of the immune response to a synthetic vaccine against Plasmodium falciparum. Parasite Immunology, 1991, 13, 509-516.	1.5	52
331	Epitopes of the Plasmodium falciparum clustered-asparagine-rich protein (CARP) recognized by human T-cells and antibodies. Parasite Immunology, 1991, 13, 681-694.	1.5	10
332	Studies in Owl Monkeys Leading to the Development of a Synthetic Vaccine against the Asexual Blood Stages of Plasmodium Falciparum. American Journal of Tropical Medicine and Hygiene, 1990, 43, 339-354.	1.4	99
333	Immunization of Owl Monkeys with a Combination of Plasmodium Falciparum Asexual Blood-Stage Synthetic Peptide Antigens. American Journal of Tropical Medicine and Hygiene, 1990, 43, 355-366.	1.4	41
334	A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature, 1988, 332, 158-161.	27.8	415
335	Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature, 1987, 328, 629-632.	27.8	296
336	MPB59, a Widely Cross-Reacting Protein of <i>Mycobacterium bovis </i> BCG. International Archives of Allergy and Immunology, 1986, 81, 307-314.	2.1	99
337	Viral hepatitis in Colombia: A study of the "hepatitis of the Sierra Nevada de Santa Marta― Hepatology, 1985, 5, 299-304.	7.3	54
338	An analysis of in vitro T cell responsiveness in lepromatous leprosy Journal of Experimental Medicine, 1985, 162, 917-929.	8.5	82
339	Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum Journal of Experimental Medicine, 1984, 159, 1686-1704.	8.5	282
340	Association of a B-cell alloantigen with susceptibility to rheumatic fever. Nature, 1979, 278, 173-174.	27.8	157